ESMO virtual confress 2020 演題レポート 19 Sep - 21 Sep 2020

2020年9月19日~21日に完全にバーチャルで開催された 2020年 欧州臨床腫瘍学会学術集会(ESMO Virtual Congress 2020)より、上部消化菅、肝胆膵の注目演題のレポートをお届けします。演題レポートの冒頭には、臨床研究の第一線で活躍する監修ドクターのコメントを掲載します。

特別オンライン座談会

演題レポート

Presidential Symposium

#LBA6_PR
胃癌
食道胃接合部癌
食道癌

Nivolumab (NIVO) Plus Chemotherapy (Chemo) Versus Chemo as First-Line (1L) Treatment for Advanced Gastric Cancer/Gastroesophageal Junction Cancer (GC/GEJC)/Esophageal Adenocarcinoma (EAC): First Results of the CheckMate 649 Study

Markus Moehler, et al.

#LBA7_PR
胃癌
食道胃接合部癌

Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Patients with Previously Untreated Advanced or Recurrent Gastric/Gastroesophageal Junction (G/GEJ) Cancer: ATTRACTION-4 (ONO-4538-37) Study

Narikazu Boku, et al.

#LBA8_PR
食道癌

Pembrolizumab Plus Chemotherapy Versus Chemotherapy as First-Line Therapy in Patients with Advanced Esophageal Cancer: The Phase 3 KEYNOTE-590 Study

Ken Kato, et al.

#LBA9_PR
食道癌
食道胃接合部癌

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer (EC/GEJC) Following Neoadjuvant Chemoradiation Therapy (CRT): First Results of the CheckMate 577 Study

Ronan J. Kelly, et al.

Proffered Paper Session

#LBA65
膵臓癌

The Canadian Cancer Trials Group PA.7 Trial: Results of a Randomized Phase II Study of Gemcitabine (GEM) and Nab-Paclitaxel (Nab-P) vs. GEM, Nab-P, Durvalumab (D) and Tremelimumab (T) as First Line Therapy in Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

Daniel J. Renouf, et al.